Tarsus Pharmaceuticals (TARS) announced the commencement of an underwritten public offering of $100M of shares of its common stock. All shares ...
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) has been given an average recommendation of “Buy” by the seven ...
Jefferies raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $58 from $54 and keeps a Buy rating on the shares. The firm says ...
9d
FOX 4 Dallas-Fort Worth on MSNBorder Patrol identifies strange object that fell from sky in North TexasU.S. Customs and Border Protection (CBP) has claimed an object that people from Quinlan say fell from the sky on Tuesday ...
Tarsus Pharmaceuticals sees growth with Xdemvy's $180M sales in 2024. Read this article to know what makes TARS stock a BUY for growth investors.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
However, according to the Commonwealth Ombudsman, designated communications providers (DCPs) are receiving duplicated ...
The Dakota Cougars defeated the Anchor Bay Tars 52-47 on Wednesday, March 5 to advance to the Division 1 district ...
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results